Cipro vs. Bactrim
See how Cipro and Bactrim compare on approved uses, dosing, side effects, and cost.
Key Takeaways
Cipro carries an FDA black box warning for tendon rupture and nerve damage, while Bactrim carries no such warning but can trigger severe skin reactions and is unsafe for infants under 2 months old.
Cipro treats urinary, skin, bone, and respiratory infections in short 3 to 14 day courses, while Bactrim is the go-to choice for Pneumocystis pneumonia, ear infections in children, and traveler's diarrhea.
Both drugs are older, widely used generic antibiotics, but they come from different drug classes with different resistance patterns and side effect profiles.
Cipro vs. Bactrim Drug Summary
Cipro
Cipro (ciprofloxacin) is a fluoroquinolone antibiotic used for urinary tract, respiratory, skin, bone, and abdominal infections, plus anthrax and plague exposure. It works by blocking bacterial DNA replication and is taken as a tablet, liquid, or IV infusion, usually twice a day for 3 to 14 days depending on the infection.
Bactrim
Bactrim (sulfamethoxazole and trimethoprim) is a combination sulfonamide antibiotic used for urinary tract infections, ear infections in children, traveler's diarrhea, and Pneumocystis pneumonia. It blocks two sequential steps in bacterial folate production and is taken as a tablet, liquid, or IV infusion, usually twice a day for 5 to 21 days depending on the infection.
Cipro vs. Bactrim Side Effects
Cipro
Bactrim
Cipro vs. Bactrim Dosage
Cipro
Bactrim
| STAGE | DOSE | WHEN |
| Starting dose | 250 mg every 12 hours | At the start |
| Maximum dose | 750 mg every 12 hours | If needed |
| Dose changes | 2 increases | As tolerated |
| STAGE | DOSE | WHEN |
| Starting dose | 800 mg/160 mg every 12h | At the start |
| Maximum dose | 8-10 mg/kg/day div q6-12h | If needed |
| Dose changes | 3 increases | As tolerated |
Cipro
| STAGE | DOSE | WHEN |
| Starting dose | 250 mg every 12 hours | At the start |
| Maximum dose | 750 mg every 12 hours | If needed |
| Dose changes | 2 increases | As tolerated |
Bactrim
| STAGE | DOSE | WHEN |
| Starting dose | 800 mg/160 mg every 12h | At the start |
| Maximum dose | 8-10 mg/kg/day div q6-12h | If needed |
| Dose changes | 3 increases | As tolerated |
Cipro vs. Bactrim Indications
Cipro
Cipro is FDA-approved for a wide range of bacterial infections in adults, including complicated and uncomplicated urinary tract infections, skin and bone infections, and lower respiratory tract infections. It is also approved for infectious diarrhea, typhoid fever, and post-exposure prophylaxis for inhalational anthrax and plague.
Uncomplicated and complicated UTIs
Skin, bone, and joint infections
Lower respiratory tract infections
Inhalational anthrax and plague exposure
Infectious diarrhea and typhoid fever
Bactrim
Bactrim is FDA-approved to treat urinary tract infections, acute ear infections in children, and flare-ups of chronic bronchitis in adults. It is also approved for shigellosis, traveler's diarrhea, and both treatment and prevention of Pneumocystis jirovecii pneumonia.
Urinary tract infections
Acute ear infections in children
Chronic bronchitis flare-ups
Pneumocystis pneumonia treatment and prevention
Shigellosis and traveler's diarrhea
Cipro vs. Bactrim Pros and Cons
Cipro
Cipro's fluoroquinolone class gives it broad activity against tough Gram-negative bacteria, including Pseudomonas, and it comes in an IV form for severe infections. That same class carries an FDA black box warning for tendon, nerve, and central nervous system damage.
Pros
Effective against Pseudomonas and other tough Gram-negative bacteria
Available as IV for hospitalized or severe infections
Short 3-day course for uncomplicated UTIs
Used for anthrax and plague exposure
Cons
Black box warning for tendon rupture and nerve damage
FDA advises against use for sinusitis or bronchitis when alternatives exist
Can interact with antacids, tizanidine, and other common drugs
Risk of C. diff-associated diarrhea
Bactrim
Bactrim's combination of two antibacterial agents blocks bacterial folate production at two separate steps, giving it a niche role in Pneumocystis pneumonia and off-label MRSA skin infections. It does not carry a black box warning, but it is contraindicated in infants and in patients with certain blood or enzyme disorders.
Pros
No black box warning like fluoroquinolones
Preferred option for Pneumocystis pneumonia
Commonly used off-label for MRSA skin infections
Long track record since FDA approval in 1973
Cons
Contraindicated in infants under 2 months old
Risk of severe skin reactions like Stevens-Johnson syndrome
Unsafe for patients with G6PD deficiency
Not effective for strep throat
Common Symptoms and Related Diseases You Can Explore
Explore a range of common symptoms the Doctronic Symptom Checker can help you understand.